Intellectual property and process patent related issues.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to internal tax and R&D amortization credit in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Duration: July 1, 2013
to
present
General Issues: Copyright/Patent/Trademark , Medicare/Medicaid , Taxation/Internal Revenue Code , Manufacturing , Budget/Appropriations , Medical/Disease Research/Clinical Labs , Trade (Domestic & Foreign) , Health Issues
Spending: about $2,135,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Related Foreign Entities:
F. Hoffmann-La Roche Ltd. (CH 4070-Basel, SUI); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jeff Forbes Staff Director, Senate Finance Committee
Chief of Staff, Senator Max Baucus
Deputy Asst, Special Asst, Deputy Director EOP
Libby Greer Chief of Staff, Rep. Allen Boyd
Derrick White Deputy Press Secretary, Senator Orrin Hatch
Cindy Brown Leg Assistant, Rep. Stupak, 1993-1994, Leg Director, Rep. Kind, 1999-2002, Chief of Staff, Rep. Kind, 2003-2009
Barrett Thornhill Legislative Assistant, Sen. Mike Crapo (2003-2006); Legislative Assistant, Rep. Pat Toomey (2002-2003); Legislative Assistant, Rep. Charlie Norwood (2001-2002)
Francesca McCrary Legislative Assistant, Rep. Elijah Cummings (2016-2017); Professional Staff, House Oversight & Reform Committee (2016)
Michael Williams Legislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Brian Jones (2019); Legislative Correspondent, Sen. Brian Jones (2018-2019)
Williams, MichaelLegislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Brian Jones (2019); Legislative Correspondent, Sen. Brian Jones (2018-2019)
Jay Driscoll n/a
Zachary Williams n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 13.
Original Filing: 301549090.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to funding of the strategic national stockpile; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 16.
Original Filing: 301525688.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to funding of the strategic national stockpile; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 17, 2023.
Original Filing: 301503184.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to funding of the strategic national stockpile; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 16, 2023.
Original Filing: 301477050.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to tax; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to funding of the strategic national stockpile; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 19, 2023.
Original Filing: 301456306.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to tax; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to funding of the strategic national stockpile; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 14, 2023.
Original Filing: 301427660.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in the H.R.5376 - Build Back Better Act; Issues related to tax; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to funding of the strategic national stockpile; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413305.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in the H.R.5376 - Build Back Better Act; Issues related to tax; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to funding of the strategic national stockpile; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 16, 2022.
Original Filing: 301381713.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in the H.R.5376 - Build Back Better Act; Issues related to tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to funding of the strategic national stockpile.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 15, 2022.
Original Filing: 301357312.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to internal tax and R&D amortization credit in the H.R.5376 - Build Back Better Act; Issues related to tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 16, 2022.
Original Filing: 301323416.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301647.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 16, 2021.
Original Filing: 301278159.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 17, 2021.
Original Filing: 301255066.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding the Center for Medicare and Medicaid Innovation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 19, 2021.
Original Filing: 301235987.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Capability Maturity Model Integration (CMMI).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 18, 2020.
Original Filing: 301212670.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Capability Maturity Model Integration (CMMI).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 18, 2020.
Original Filing: 301192865.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Capability Maturity Model Integration (CMMI).
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 18, 2020.
Original Filing: 301171761.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Capability Maturity Model Integration (CMMI).
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121433.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Capability Maturity Model Integration (CMMI).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 19, 2019.
Original Filing: 301071954.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to RX drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 19, 2019.
Original Filing: 301051234.xml
Lobbying Issues
Intellectual property and process patent related issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to RX drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301034670.xml
Lobbying Issues
Intellectual property and process patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to RX drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Right to Try.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2018
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 22, 2019.
Original Filing: 301013543.xml
Lobbying Issues
Intellectual property and process patent issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX drug pricing; Issues related to the International Pricing Index for Medicare Part D.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Right to Try; Issues related to Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, S. 2852.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 18, 2018.
Original Filing: 300989542.xml
Lobbying Issues
Intellectual property and process patent issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX drug pricing.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Right to Try; Issues related to Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, S. 2852.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 19, 2018.
Original Filing: 300969769.xml
Lobbying Issues
Intellectual property and process patent issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX drug pricing.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Right to Try; Issues related to Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, S. 2852.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300949419.xml
Lobbying Issues
Intellectual property and process patent issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX drug pricing.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Right to Try.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2017
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300935007.xml
Lobbying Issues
Intellectual property and process patent issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX drug pricing.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Right to Try.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 16, 2017.
Original Filing: 300904845.xml
Lobbying Issues
Intellectual property and process patent issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug reimportation; Issues related to RX pricing.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Right to Try.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2017
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 19, 2017.
Original Filing: 300890503.xml
Lobbying Issues
Intellectual property and process patent issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 19, 2017.
Original Filing: 300870946.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Medicare and Medicaid Coverage and Reimbursement; Issues pertaining to 340B.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 19, 2017.
Original Filing: 300849804.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; Issues relating to Prescription Drug User Fee Act and ASP +6 and Part B Demo; Issues related to comparative effectiveness and follow-on biologics; Issues related to FDA repeal of Avastin; Issues related to coverage of Lucentis and Avastin; Issues related to 340B; Issues related to the 21st Century Cures Act, H.R. 6.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Vice President's National Cancer Moonshot Initiative.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 19, 2016.
Original Filing: 300831856.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6 and Part B Demo; issues related to comparative effectiveness and follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; issues related to 340B; issues related to the 21st Century Cures Act, H.R. 6.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Vice President's National Cancer Moonshot Initiative.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300816556.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6 and Part B Demo; issues related to comparative effectiveness and follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B; issues related to the 21st Century Cures Act, H.R. 6.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Vice President's National Cancer Moonshot Initiative.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300801583.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B; issues related to the 21st Century Cures Act, H.R. 6.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Vice President's National Cancer Moonshot Initiative.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Forbes-Tate lobbied for Genentech , earning $45,000. The report was filed on Jan. 20, 2016.
Original Filing: 300782370.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics; issues related to coverage of Lucentis and Avastin; Issues related to 340B; issues related to the 21st Century Cures Act, H.R. 6
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, Forbes-Tate lobbied for Genentech , earning $45,000. The report was filed on Oct. 20, 2015.
Original Filing: 300761668.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B; issues related to the 21st Century Cures Act, H.R. 6.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
In Q2, Forbes-Tate lobbied for Genentech , earning $45,000. The report was filed on July 20, 2015.
Original Filing: 300745579.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2015
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 17, 2015.
Original Filing: 300718576.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 20, 2015.
Original Filing: 300703068.xml
Lobbying Issues
Intellectual Property and Process Patent Issues-
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/H.R. 1102]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 4438 - American Research and Competitiveness Act of 2014; Issues related to 340B.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Oct. 20, 2014.
Original Filing: 300683597.xml
Lobbying Issues
Intellectual Property and Process Patent Issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/H.R. 1102]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 4438- American Research andCompetitiveness Act of 2014; Issues related to 340B.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2014
In Q2, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on July 19, 2014.
Original Filing: 300663495.xml
Lobbying Issues
Intellectual Property and Process Patent Issues (all provisions).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/H.R. 1102]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 4438- American Research andCompetitiveness Act of 2014; Issues related to 340B.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2014
In Q1, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on April 21, 2014.
Original Filing: 300645874.xml
Lobbying Issues
Intellectual Property and Process Patent Issues - H.R. 1908, Patent Reform Act (all provisions).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942 American Research and Competitiveness Act of 2011; Issues related to 340B
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2013
In Q4, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 21, 2014.
Original Filing: 300622723.xml
Lobbying Issues
Intellectual Property and Process Patent Issues - H.R. 1908, Patent Reform Act (all provisions).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription
Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and
follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942 American Research and Competitiveness Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2013
In Q3, Forbes-Tate lobbied for Genentech , earning $50,000. The report was filed on Jan. 6, 2014.
Original Filing: 300611540.xml
Lobbying Issues
Intellectual Property and Process Patent Issues - H.R. 1908, Patent Reform Act (all provisions).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription
Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and
follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942 American Research and Competitiveness Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2013
Forbes-Tate filed a lobbying registration on Oct. 3, 2013 to represent Genentech, effective July 1, 2013.
Original Filing: 300590845.xml
Issue(s) they said they’d lobby about: Issues related to Intellectual Property and Process Patent Issues - HR 1908, Patent Reform Act (all provisions); Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues re: comparative effectiveness and followon biologics; FDA repeal of Avastin; coverage of Lucentis & Avastin; trade issues; & HR 942- American Research & Competiveness Act of 2011. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...